{"id":"cbt-004","safety":{"commonSideEffects":[{"rate":null,"effect":"Cytokine release syndrome"},{"rate":null,"effect":"T cell activation-related toxicity"},{"rate":null,"effect":"Infusion-related reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"CBT-004 functions as a bispecific antibody or T cell-engaging therapeutic that bridges T cells and tumor cells, enabling direct cytotoxic killing. By engaging both CD3 on T cells and a tumor-associated antigen, the drug facilitates immune synapse formation and T cell activation against cancer cells. This approach leverages the patient's own immune system to target malignant cells.","oneSentence":"CBT-004 is a T cell engager designed to redirect patient T cells to recognize and eliminate cancer cells expressing a specific tumor antigen.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T03:50:10.712Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Solid tumors (specific antigen target and indication under investigation in Phase 2)"}]},"trialDetails":[{"nctId":"NCT04884256","phase":"PHASE2","title":"Safety and Efficacy Study of CBT-004 in Patients With Vascularized Pinguecula","status":"COMPLETED","sponsor":"Cloudbreak Therapeutics, LLC","startDate":"2023-12-21","conditions":"Pinguecula","enrollment":88}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"CBT-004","genericName":"CBT-004","companyName":"Cloudbreak Therapeutics, LLC","companyId":"cloudbreak-therapeutics-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CBT-004 is a T cell engager designed to redirect patient T cells to recognize and eliminate cancer cells expressing a specific tumor antigen. Used for Solid tumors (specific antigen target and indication under investigation in Phase 2).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}